Group 1 - Global Printing announced that shareholder Hong Kong Yuanshi International Co., Ltd. plans to reduce its stake by up to 3.2004 million shares, accounting for 1% of the total share capital, due to personal funding needs [1] - Sunflower intends to acquire 100% equity of Xi Pu Materials and 40% equity of Zhejiang Beid Pharmaceutical through a combination of share issuance and cash payment, with stock resuming trading on September 22, 2025 [1][2] - Crown Zhong Ecology is planning a change in control, leading to a temporary suspension of its stock and convertible bonds due to significant uncertainties [2] Group 2 - China Oil Engineering's wholly-owned subsidiary signed a $513 million EPC contract for an LNG pipeline project in the UAE, covering approximately 180.5 kilometers of natural gas pipeline with a 36-month construction period [3] - Shanxi Fenjiu announced that shareholder Huachuang Xinrui (Hong Kong) Co., Ltd. plans to reduce its stake by up to 16.2006 million shares, representing no more than 1.33% of the total share capital [4] - Brother Technology's subsidiary received a drug registration certificate for Iopamidol injection, which is included in the national medical insurance catalog [5] Group 3 - Lin Yang Energy is expected to win a bid for a metering equipment project from the State Grid, with an estimated total bid amount of approximately 142 million yuan [6] - Huahai Chengke received approval from the China Securities Regulatory Commission for issuing shares and convertible bonds to purchase assets and raise no more than 800 million yuan in matching funds [8] - Jindi Co. signed a framework agreement to acquire controlling interest in Unico Precision, which specializes in manufacturing gears and automotive parts [10] Group 4 - Ruifeng High Materials announced that its major shareholder plans to reduce its stake by up to 2.4 million shares, accounting for 0.9584% of the total share capital [12] - Changliang Technology's director plans to reduce his stake by 1.05 million shares, representing 0.129% of the total share capital [14] - Zhongjing Food's director plans to reduce his stake by up to 150,000 shares, accounting for 0.10% of the total share capital [16] Group 5 - Haitai Technology announced that two shareholders plan to reduce their stakes by a total of up to 2.53% of the total share capital [18] - Zhenlei Technology's chairman is under detention but the company states that control has not changed and operations remain normal [20] - Huakang Co. plans to distribute a cash dividend of 0.2 yuan per share, totaling approximately 60.61 million yuan [19]

Core Viewpoint - The announcement details the adjustment of the conversion price for the company's convertible bonds due to the implementation of a profit distribution plan for the first half of 2025, resulting in a decrease in the conversion price from 16.46 CNY to 16.26 CNY per share [2][3][6]. Group 1: Conversion Price Adjustment - The initial conversion price of the "Huakang Convertible Bonds" was set at 22.66 CNY per share, which has undergone several adjustments due to various corporate actions [5]. - The conversion price was adjusted to 16.89 CNY per share on May 28, 2024, and further adjusted to 16.39 CNY on April 24, 2025, before the latest adjustment [5]. - The new conversion price of 16.26 CNY per share will take effect on September 29, 2025, following the distribution of a cash dividend of 0.2 CNY per share [3][6]. Group 2: Profit Distribution Plan - The company plans to distribute a cash dividend of 0.2 CNY per share, amounting to a total of approximately 6,060.99622 million CNY based on the total share capital of 30,304.9811 million shares [11][13]. - The profit distribution plan was approved during the second extraordinary general meeting of shareholders held on September 8, 2025 [11]. - The distribution will be executed through the Shanghai Clearing House, with specific procedures outlined for both unrestricted and restricted shareholders [14][16].

浙江华康药业股份有限公司 关于因实施权益分派调整"华康转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 因实施 2025 年半年度权益分派，本公司的相关证券停复牌情况如下： | 证券代码 | 证券简称 | 停复牌类型 | 停牌起 | 停牌 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | | | | 始日 | 期间 | | | | 111018 | 华康转债 | 可转债转股复牌 | | | 2025/9/26 | 2025/9/29 | 一、转股价格调整依据 | 证券代码：605077 | 证券简称：华康股份 | 公告编号：2025-081 | | --- | --- | --- | | 债券代码：111018 | 债券简称：华康转债 | | 二、转股价格历次调整情况 本次发行可转换公司债券"华康转债"的初始转股价格为 22.66 元/股。历次转股 价格调整情况如下： 因公司实施 2023 年度权益分派，"华康转债"转 ...

| 证券代码：605077 | 证券简称：华康股份 | 公告编号：2025-080 | | --- | --- | --- | | 债券代码:111018 | 债券简称:华康转债 | | 浙江华康药业股份有限公司 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/9/26 | － | 2025/9/29 | 2025/9/29 | 差异化分红送转： 否 一、通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 9 月 8 日的2025年第二次临时股东大会审议 通过。 2025年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.2元 相关日期 二、分配方案 1.发放年度：2025年半年度 2.分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司" ...

| 证券代码：605077 | 证券简称：华康股份 | 公告编号：2025-079 | | --- | --- | --- | | 债券代码：111018 | 债券简称：华康转债 | | 浙江华康药业股份有限公司 关于实施 2025 年中期权益分派"华康转债"停止转股 的提示性公告 本次权益分派方案实施后，公司将依据《浙江华康药业股份有限公司向不特 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券停复牌情况：适用 因实施权益分派,本公司的相关证券停复牌情况如下： | 证券代码 | 证券简称 | 停复牌类型 | 停牌起始日 | 停牌 | 停牌终 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | | | | | 期间 | 止日 | | | 111018 | 华康转债 | 可转债转股停牌 | 2025/9/19 | | | | 权益分派实施公告前一交易日（2025 年 9 月 19 日）至权益分派股权登记 日期间，本公司可转债将停止转股。 一、本次权益分派 ...

证券日报网讯 9月8日晚间，华康股份发布公告称，公司董事会于近日收到非独立董事杜勇锐先生提交 的书面辞职报告，因公司内部工作调整，杜勇锐先生申请辞去公司第六届董事会非独立董事职务，辞职 后仍继续在公司担任其他职务。公司于2025年9月8日召开职工代表大会，经全体与会职工代表认真审议 并表决，一致同意选举杜勇锐先生为公司第六届董事会职工代表董事，任期自本次职工代表大会选举通 过之日起至第六届董事会任期届满之日止。 （文章来源：证券日报） ...

Core Points - Huakang Co., Ltd. announced the resignation of non-independent director Du Yongrui due to internal work adjustments, while he will continue to serve as the overseas market director [1] - The company will hold a staff representative meeting on September 8, 2025, to elect Du Yongrui as a staff representative director for the sixth board of directors, with a term lasting until the current board's term ends [1]

Group 1 - The company announced the holding of its second extraordinary general meeting of shareholders for 2025 on September 8, 2025 [2] - The meeting approved multiple proposals, including the mid-term profit distribution plan for 2025 [2]

| 证券代码：605077 | 证券简称：华康股份 | 公告编号：2025-078 | | --- | --- | --- | | 债券代码：111018 | 债券简称：华康转债 | | 浙江华康药业股份有限公司 关于公司非独立董事辞职暨选举职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事离任情况 浙江华康药业股份有限公司（以下简称"公司"）董事会于近日收到非独立 董事杜勇锐先生提交的书面辞职报告，因公司内部工作调整，杜勇锐先生申请辞 去公司第六届董事会非独立董事职务，辞职后仍继续在公司担任其他职务。具体 情况如下： (一)提前离任的基本情况 | 姓名 | 离任职 | 离任时 | | 原定任期 | | | | 是否继续在上 | 具体职务 | | 是否存在未 履行完毕的 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 务 | 间 | | 到期日 | | | 离任原因 | 市公司及其控 股子公 ...

贵公司已向本所承诺：贵公司向本所律师所提供的文件和所作陈述及说明是 完整的、真实的和有效的，有关原件及其上面的签字和印章是真实的，且一切足 以影响本法律意见书的事实和文件均已向本所披露，无任何隐瞒、疏漏之处。 在本法律意见书中，本所律师根据《股东会规则》的要求，仅就本次股东大 会的召集、召开程序是否合法及是否符合《公司章程》、出席会议人员资格和会 议召集人资格的合法有效性、会议表决程序和表决结果的合法有效性发表意见， 而不对本次股东大会所审议的议案内容和该等议案中所表述的事实或数据的真 实性和准确性发表意见。 本所律师仅根据本法律意见书出具日前发生或存在的事实及有关的法律、行 政法规、规范性文件及《公司章程》的规定发表法律意见。本法律意见书仅供本 次股东大会之目的而使用，不得用于其他任何目的或用途。本所同意，贵公司可 以将本法律意见书作为贵公司本次股东大会公告材料，随其他需公告的信息一起 国浩律师（杭州）事务所（以下简称"本所"）接受贵公司的委托，指派本 所律师出席贵公司于 2025 年 9 月 8 日在浙江省衢州市开化县华埠镇华工路 18 号公司四楼会议室召开的 2025 年第二次临时股东大会（以下简称"本 ...